|
A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies. |
| |
|
Honoraria - Astellas Pharma |
Consulting or Advisory Role - D.E. Shaw Research |
Travel, Accommodations, Expenses - Roche/Genentech; Sanofi |
| |
|
Employment - HCA Healthcare |
| |
|
Stock and Other Ownership Interests - RNA Guardian; RNA Guardian (I) |
Honoraria - Amphista Therapeutics; RApport Global; Theolytics; UCB |
Consulting or Advisory Role - Oxford Investment Consultants; UCB |
Research Funding - Astex Pharmaceuticals (Inst); BerGenBio (Inst); MINA THERAPEUTICS (Inst); MSD Oncology (Inst); Nucana (Inst); Nurix (Inst); Redx Pharma (Inst); UCB (Inst) |
Patents, Royalties, Other Intellectual Property - WO 2016075455 A1 circulating LARP1 |
| |
|
Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro |
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Novartis; Onxeo; Pierre Fabre; Sanofi/Aventis |
Research Funding - AstraZeneca/MedImmune (Inst) |
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology |
| |
|
Employment - Northern Centre For Cancer Care |
| |
|
|
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Guardant Health; Janssen; OM Pharma; Roche; Seagen |
Speakers' Bureau - Janssen; Roche |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio; BerGenBio; Immutep |
| |
|
Consulting or Advisory Role - AstraZeneca (Inst); Elsevier (Inst); Roche/Genentech (Inst) |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Guardant Health (Inst) |
| |
|
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst) |
Consulting or Advisory Role - Karus Therapeutics (Inst) |
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst) |
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst) |
Expert Testimony - Medivir (Inst) |
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre |
Other Relationship - Genmab (Inst) |
| |
|
|
Stock and Other Ownership Interests - Nurix |
Patents, Royalties, Other Intellectual Property - Compugen Inc, Nurix Therapeutics |
| |
|
Employment - Allogene Therapeutics |
| |
|
|
Stock and Other Ownership Interests - Nurix |
Travel, Accommodations, Expenses - Nurix |
| |
|
|
Stock and Other Ownership Interests - Nanobiotix |
| |
|
No Relationships to Disclose |
| |
|
Employment - Institute of Cancer Research |
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex |
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex |
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex |
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex |
| |
|
Employment - Hospital Corporation of America |
Honoraria - Bayer; BeiGene; Bicycle Therapeutics; Guardant Health; Merck KGaA; Roche; SERVIER |
Consulting or Advisory Role - Engitix; iOnctura |
Research Funding - Sarah Cannon Research Institute |